• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    药

    药明康德

    WuXi AppTec Inc.
    企业
    467论文总数
    8,205引用总数

    论文量&引用量时间轴

    机构学者

    论文(467)

    年份
    起
    –
    止
    排序
    1Targeting Autocrine Retinoic Acid Signaling by ALDH1A2 Inhibition Enhances Antitumor Dendritic Cell Vaccine Efficacy
    Cao Fang,Mark Esposito, Ulrike Hars, Robert T. Byrne,Bokai Song, Jian Huang,Asael Roichman, Lawrence Shue, Xiaobing Cheng, John Proudfoot, Demin Zhao,Yong Wei,

    Strategies to stimulate dendritic cell (DC) activity, such as ex vivo generation and priming of DC vaccines, have been explored as cancer immunotherapies owing to their potential to elicit antitumor T cell responses. Despite decades of research, the success of DC vaccines has been limited, potentially because of unidentified tolerance-enforcing mechanisms. Here we show that GM-CSF–IL-4-induced differentiating DCs express ALDH1A2 and produce retinoic acid, inhibiting DC maturation. Genetic knockout of Aldh1a2 releases this natural brake and enhances DC function. We further develop an ALDH1A2 inhibitor with high potency, favorable drug-like properties and no evidence of off-target effects. Treatment with this inhibitor promotes DC activity, which in turn enhances antigen-specific T cell responses, improving the efficacy of DC vaccines. Our study demonstrates the unique role of the ALDH1A2–retinoic acid axis in regulating DC functions and further presents a new small-molecule inhibitor of ALDH1A2 as a potential immunotherapeutic agent for cancer. Differentiating DCs express ALDH1A2, which produces retinoic acid and suppresses DC activity. Blocking this pathway with a new inhibitor, KyA33, enhances immune responses and boosts the effectiveness of DC cancer vaccines in mouse models.

    2026Nature Immunology(2026)引用:4
    引用
    AI阅读
    加入学术空间
    2Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C
    Nicholas F Endres,Steven Do, Rana Mroue,Jack A Terrett, Matt Saabye, Angela Oh,Thomas Hunsaker, Emily Chan,John C Tran, Lan K Nguyen, Qihui Lian, Taylur P Ma,

    KRAS G12C is one of the most prevalent oncogenic mutations in nonsmall cell lung cancer. Herein we describe the discovery and optimization of divarasib (GDC-6036), an orally available, highly potent, and selective covalent KRAS G12C inhibitor. We demonstrate a significant noncovalent binding component of divarasib that contributes to its potency and rapid kinetics. Divarasib has greater potency and kinetics of alkylation compared with other KRAS G12C inhibitors in vitro and shows robust tumor growth inhibition in multiple KRAS G12C-positive cell lines.

    2026Journal of medicinal chemistry(2026)引用:2
    引用
    AI阅读
    加入学术空间
    3Discovery and Optimization of a Potent, Efficacious, and Brain-Penetrant Inhibitor of KRAS G12C.
    Matthew L Landry,Sushant Malhotra, Maureen Beresini,Connie Chan, Emily Chan, Cecile C de la Cruz,Nicholas F Endres,Marie Evangelista,Amy Gustafson, Dennis Hu,Thomas Hunsaker, Peter Hsu,

    Mutant KRAS is highly prevalent in human cancer and has been actively pursued as a target for drug discovery. Much progress has been made in drugging KRAS G12C, owing to the ability of inhibitors to covalently target its oncogenic cysteine mutation at codon 12. A number of KRAS G12C inhibitors have advanced to clinical development and are being investigated for the treatment of a variety of solid tumors. Notably, many patients with KRAS G12C-positive non-small cell lung cancer develop brain metastases. Herein, we report the discovery and development of a brain-penetrant inhibitor of KRAS G12C using divarasib as a starting point. Optimization efforts focused on reducing molecular weight and topological polar surface area as well as shielding of hydrogen bond donors. In this manner, active transport by both P-gp and breast cancer resistance protein (BCRP) was attenuated, and high exposure in rodent brain tissue was achieved.

    2026Journal of medicinal chemistry(2026)引用:2
    引用
    AI阅读
    加入学术空间
    4Ugi-Type Reaction Enables Access to Fused Imidazole Derivatives for DNA-Encoded Library Technology.
    Hao Guo, Zitao Li, Gaonan Wang, Biyu Zhang, Mengxue Wang, Lu Liu, Alexander L Satz,Wenji Su,Letian Kuai,Qi Zhang

    This study presents a DNA-compatible synthesis of diverse N-fused imidazopyridines via a catalyst-free Ugi-type multicomponent reaction using TMSCN as a functional isonitrile equivalent. The desilylation activation occurs efficiently in water without additional catalysts. The method exhibits a broad substrate scope for aldehydes and heterocyclic amidines and excellent chemoselectivity, underscoring its utility for constructing privileged heteroaromatic scaffolds in DNA-encoded library technology.

    2026Bioconjugate chemistry(2026)引用:1
    引用
    AI阅读
    加入学术空间
    5MuCO: Generative Peptide Cyclization Empowered by Multi-stage Conformation Optimization
    Yitian Wang,Fanmeng Wang, Angxiao Yue, Wentao Guo, Yaning Cui,Hongteng Xu

    Modeling peptide cyclization is critical for the virtual screening of candidate peptides with desirable physical and pharmaceutical properties. This task is challenging because a cyclic peptide often exhibits diverse, ring-shaped conformations, which cannot be well captured by deterministic prediction models derived from linear peptide folding. In this study, we propose MuCO (Multi-stage Conformation Optimization), a generative peptide cyclization method that models the distribution of cyclic peptide conformations conditioned on the corresponding linear peptide. In principle, MuCO decouples the peptide cyclization task into three stages: topology-aware backbone design, generative side-chain packing, and physics-aware all-atom optimization, thereby generating and optimizing conformations of cyclic peptides in a coarse-to-fine manner. This multi-stage framework enables an efficient parallel sampling strategy for conformation generation and allows for rapid exploration of diverse, low-energy conformations. Experiments on the large-scale CPSea dataset demonstrate that MuCO significantly outperforms state-of-the-art methods in consistently in physical stability, structural diversity, secondary structure recovery, and computational efficiency, making it a promising computational tool for exploring and designing cyclic peptides.

    2026ICML 2026(2026)引用:1
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 467 篇论文

    合作机构(100)

    基因泰克合作论文 33
    默克制药公司合作论文 22
    康龙化成(北京)新药技术股份有限公司合作论文 10
    辉瑞合作论文 9
    Syneos Health合作论文 9
    纽约州立大学合作论文 8
    葛兰素史克合作论文 8
    阿斯利康合作论文 7
    浙江大学合作论文 7
    Pharma Medica Research (Canada)合作论文 5

    机构统计